Provider Briefing: Cequa Access and Availability in 2026

If your patients are reporting difficulty filling Cequa (Cyclosporine ophthalmic solution 0.09%) prescriptions, the issue is real — though not driven by a traditional supply shortage. Cequa remains available from Sun Pharmaceutical Industries, but a combination of insurance barriers, limited retail pharmacy stocking, and the absence of a generic formulation creates persistent access challenges.

This briefing covers the current supply landscape, prescribing implications, cost and coverage considerations, and practical tools you can use to help patients access Cequa in 2026.

Supply Timeline and Current Status

Cequa was FDA-approved in August 2018 under NDA 210913 as a 505(b)(2) application. It is manufactured by Sun Pharmaceutical Industries and has not been listed on the FDA Drug Shortage Database at any point since its approval.

The availability challenges patients experience are not manufacturing- or distribution-related in the traditional sense. Instead, they stem from downstream factors:

• Retail pharmacy stocking decisions — Many large chain pharmacies do not maintain Cequa in their standard inventory due to low fill volume and high acquisition cost
• Payer-driven fill barriers — Prior authorization requirements, step therapy protocols, and formulary exclusions reduce the number of prescriptions that proceed to dispensing
• Specialty channel concentration — Sun Pharma routes a significant portion of Cequa distribution through its partnership with PhilRx, which may not be a pharmacy patients are familiar with

In practical terms: the drug is manufactured, available through wholesalers, and not in shortage — but a patient walking into a typical CVS or Walgreens may encounter an "out of stock" or "not carried" response.

Prescribing Implications

Formulary Position

Cequa occupies a challenging formulary position in 2026. Most commercial payers and Medicare Part D plans classify it as non-preferred or exclude it from formulary entirely. Common payer requirements include:

• Step therapy: Trial of artificial tears followed by generic Cyclosporine 0.05% (Restasis equivalent) before Cequa is considered
• Prior authorization: Documentation of diagnosis (keratoconjunctivitis sicca / dry eye disease), treatment history, and clinical rationale for Cequa specifically
• Quantity limits: Typically 60 vials per 30 days (consistent with BID dosing in both eyes)

When initiating Cequa, building the step therapy documentation into the clinical workflow upfront — documenting artificial tear failure and generic cyclosporine trial — can streamline the PA process significantly.

Clinical Differentiation

Cequa's 0.09% cyclosporine concentration with NCELL nanomicellar delivery technology positions it between generic Cyclosporine 0.05% and the newer Vevye (Cyclosporine 0.1%). Key clinical considerations:

• NCELL technology is designed to enhance corneal penetration of cyclosporine compared to emulsion-based formulations
• Clinical trials (Phase 2b/3) demonstrated statistically significant improvement in Schirmer's tear test scores vs. vehicle at 12 weeks
• The 0.09% concentration provides a higher dose than Restasis/generic 0.05% while maintaining tolerability
• Most common adverse event: instillation site pain (22%) and conjunctival hyperemia (6%)

For patients who have had an inadequate response to generic Cyclosporine 0.05%, Cequa represents a reasonable next step before considering non-cyclosporine alternatives.

Current Availability Picture

The table below summarizes the practical availability landscape for Cequa in 2026:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Often not stocked; can typically order within 1-2 business days
• Independent pharmacies: Variable; more likely to stock or order specialty medications
• Specialty pharmacies (PhilRx): Primary distribution channel; reliable stock
• Mail-order pharmacies: Available through select specialty mail-order services

For providers, the most reliable dispensing pathway is often through PhilRx or another specialty pharmacy that your practice has a relationship with. This also facilitates access to manufacturer savings programs.

Cost and Access Landscape

Patient Cost Exposure

• Average wholesale price (AWP): Approximately $850-$917 for 60 single-use vials (30-day supply)
• Discounted cash price (GoodRx/similar): ~$618-$624
• With manufacturer copay card: As low as $0 for eligible commercially insured patients
• Uninsured/underinsured: PhilRx partnership provides reduced pricing options

Manufacturer Support Programs

Sun Pharma offers several access support programs that can be initiated through your practice:

• Cequa Co-Pay Program: Reduces copay to as low as $0 for commercially insured patients. BIN/PCN information available through the Cequa professional site.
• PhilRx Partnership: Full-service pharmacy support including insurance navigation, copay assistance, and alternative pricing for uninsured patients. Your office can prescribe directly to PhilRx.
• Prior Authorization Support: Sun Pharma provides a PA and Appeals Kit with template letters and clinical documentation guides for common payer requirements.

For patients with Medicare, manufacturer cash discount pricing may be available through PhilRx when the Part D plan denies coverage.

Tools and Resources for Providers

Several tools can help streamline the prescribing and dispensing process:

• Medfinder for Providers: Check real-time pharmacy availability for Cequa and other medications. Useful for directing patients to pharmacies that have stock.
• PhilRx prescriber portal: Route prescriptions directly to PhilRx for dispensing and patient support
• Cequa Prior Authorization Kit: Available through cequapro.com — includes template PA letters, appeal language, and clinical references
• Electronic prior authorization (ePA): Check if your EHR supports ePA for Cequa to reduce administrative burden

Alternative Prescribing Considerations

When Cequa access proves too difficult for a given patient, alternatives to consider include:

• Generic Cyclosporine 0.05%: Best insurance coverage and lowest cost (~$90/month); appropriate as first-line cyclosporine therapy
• Vevye (Cyclosporine 0.1%): Water-free formulation; may offer improved comfort; approved for signs and symptoms; ~$1,070/month
• Xiidra (Lifitegrast 5%): Non-cyclosporine mechanism (LFA-1 antagonist); appropriate for cyclosporine non-responders; ~$1,000/month
• Tyrvaya (Varenicline nasal spray): Novel neurostimulation approach; useful for patients who cannot tolerate topical ophthalmic medications; ~$930/month

For a patient-facing comparison, you can share our article on alternatives to Cequa with your patients.

Looking Ahead

Several factors may influence Cequa access over the coming months:

• Generic landscape: No generic Cequa 0.09% is currently approved or pending, but the competitive environment for dry eye treatments continues to expand
• Payer coverage evolution: As more dry eye options enter the market, formulary dynamics may shift — potentially improving or complicating Cequa's position depending on the plan
• Specialty pharmacy expansion: Increased adoption of specialty pharmacy pathways may improve patient access over time

Final Thoughts

Cequa remains an effective treatment option for dry eye disease, but the access landscape in 2026 requires proactive management from the prescribing practice. Building step therapy documentation into initial encounters, leveraging manufacturer support programs, and utilizing specialty pharmacy pathways are the most effective strategies for getting patients access to this medication.

For real-time availability checking, visit Medfinder for Providers. For practical guidance you can share with your patients, see our companion article: How to help your patients find Cequa in stock.